Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 3/20 | 0.31 |
| ▸ | PPARA | Q07869 | 3/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17288279 | 0.81 | FFAR1 (0.34) | SMYD2CTSKCYP3A4HTTSMN1; SMN2 | |
| SCHEMBL30298249 | 0.81 | LOX (0.40) | SMYD2LTA4HCYP3A4HTTSMN1; SMN2 | |
| SCHEMBL2021482 | 0.81 | PDE4A (0.32) | CTSK | |
| SCHEMBL3597030 | 0.74 | BTK (0.33) | SMYD2 | |
| SCHEMBL16319196 | 0.73 | BACE1 (0.34) | SMYD2CYP19A1CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL27472663 | 0.73 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2PPARD | |
| SCHEMBL19032951 | 0.73 | SMYD2 (0.35) | SMYD2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL6651489 | 0.73 | TAAR1 (0.42) | — | |
| SCHEMBL3508621 | 0.71 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL2466725 | 0.71 | PPARA (0.39) | SMYD2CYP3A4HTTSMN1; SMN2PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1557168-B1 | Biarylurea Derivatives | MSD KK (JP) | 2011-11-16 | — | — | EP | disclosed |
| US-7354946-B2 | prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-08 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| EP-1199306-B1 | BIARYLUREA DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-6958333-B1 | Biarylurea derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-10-25 | — | — | US | disclosed |
| EP-1557168-A2 | Biarylurea Derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-27 | — | — | EP | disclosed |
| EP-1199306-A1 | BIARYLUREA DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027147-A1 | Biarylurea derivatives | CDK6, CDK4, CCNI | SMYD2 2399/4885CTSK 3856/4885CYP19A1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.